Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
 Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
Inclusion Criteria:

 -  Men and women, 18-75 years old

 -  Currently meet the DSM-IV-TR criteria for Major Depressive Disorder

 -  The patient's current depressive episode must be at least 6 weeks in duration

 Exclusion Criteria:

 -  Women who are pregnant, women who will be breastfeeding during the study, and women
 with childbearing potential who are not practicing a reliable method of birth control.

 -  Patients who are considered a suicide risk

 -  Patients with a history of meeting DSM-IV-TR criteria for

 -  a. any manic or hypomanic episode

 -  b. schizophrenia or any other psychotic disorder

 -  c. obsessive-compulsive disorder.